scholarly journals Influence of Pelvic Intensity-Modulated Radiation Therapy With Concurrent Cisplatin-Based Chemotherapy of Cervical Cancer on the Vaginal Microbiome

2021 ◽  
Vol 11 ◽  
Author(s):  
Li Jiang ◽  
Bo Li ◽  
Yong Zhang ◽  
Shanshan Ma ◽  
Chang Liu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Radiation Treatment ◽  
Treatment Time ◽  
Intensity Modulated Radiation Therapy ◽  
Concurrent Chemotherapy ◽  
Composition Analysis ◽  
Vaginal Microbiome ◽  
Microbial Composition ◽  
Intensity Modulated

Pelvic intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy is an effective treatment for cervical cancer; however, radiation resistance impairs its clinical benefit. The vaginal microbiome plays an important but poorly understood role in cancer radiochemotherapy. In this study, we investigated the effects of treatment on the overall composition and alteration of the vaginal microbiome in patients receiving pelvic IMRT with concurrent cisplatin-based chemotherapy. We collected samples from twenty patients with cervical cancer and six healthy controls and performed 16S rRNA sequencing. Vaginal microbial composition analysis revealed significant differences between the two groups, but no significant differences between radiation treatment time points. However, the relative abundances of Gammaproteobacteria, Gemmatimonadetes, Gemmatimonadales, Pseudomonadales, Gemmatimonadaceae, Rikenellaceae, Acinetobacter, Desulfovibrio, Prevotella 9, Rikenellaceae RC9 gut group, Turicibacter, and the metagenome increased with time. The results encourage further study into the effects of the vaginal microbiome on cervical cancer treatment strategies, especially radiochemotherapy. Better understanding of these effects could inform new therapeutic approaches to enhance the efficacy of radiochemotherapy.

scholarly journals Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy

2018 ◽  
Vol 52 (2) ◽  
pp. 195-203 ◽  
Author(s):  
Chawalit Lertbutsayanukul ◽  
Danita Kannarunimit ◽  
Anussara Prayongrat ◽  
Chakkapong Chakkabat ◽  
Sarin Kitpanit ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Prognostic Value ◽  
Radiation Treatment ◽  
Nasopharyngeal Cancer ◽  
Intensity Modulated Radiation Therapy ◽  
Progression Free Survival ◽  
Concurrent Chemotherapy ◽  
Free Survival ◽  
Intensity Modulated ◽  
Ebv Dna

Abstract Background Plasma EBV DNA concentrations at the time of diagnosis (pre-EBV) and post treatment (post-EBV) have significant value for predicting the clinical outcome of nasopharyngeal cancer (NPC) patients. However, the prognostic value of the EBV concentration during radiation therapy (mid-EBV) has not been vigorously studied. Patients and methods This was a post hoc analysis of 105 detectable pre-EBV NPC patients from a phase II/III study comparing sequential (SEQ) versus simultaneous integrated boost (SIB) intensity-modulated radiation therapy (IMRT). Plasma EBV DNA concentrations were measured by PCR before commencement of IMRT, at the 5th week of radiation therapy and 3 months after the completion of IMRT. The objective was to identify the prognostic value of mid-EBV to predict overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS). Results A median pre-EBV was 6880 copies/ml. Mid-EBV and post-EBV were detectable in 14.3% and 6.7% of the patients, respectively. The median follow-up time was 45.3 months. The 3-year OS, PFS and DMFS rates were 86.0% vs. 66.7% (p = 0.043), 81.5% vs. 52.5% (p = 0.006), 86.1% vs. 76.6% (p = 0.150), respectively, for those with undetectable mid-EBV vs. persistently detectable mid-EBV. However, in the multivariate analysis, only persistently detectable post-EBV was significantly associated with a worse OS (hazard ratio (HR) = 6.881, 95% confident interval (CI) 1.699-27.867, p = 0.007), PFS (HR = 5.117, 95% CI 1.562–16.768, p = 0.007) and DMFS (HR = 129.071, 95%CI 19.031–875.364, p < 0.001). Conclusions Detectable post-EBV was the most powerful adverse prognostic factor for OS, PFS and DMFS; however, detectable mid-EBV was associated with worse OS, PFS especially Local-PFS (LPFS) and may facilitate adaptive treatment during the radiation treatment period.

scholarly journals Dosimetric comparison between helical tomotherapy, volume modulated arc-therapy and Fixed-Field intensity modulated radiation therapy in postoperative adjuvant radiotherapy for cervical cancer

2020 ◽  
Author(s):  
Deyang Yu ◽  
Lei Wang ◽  
Xueyuan Hu ◽  
Xin Li ◽  
Yanling Bai ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Helical Tomotherapy ◽  
Treatment Time ◽  
Intensity Modulated Radiation Therapy ◽  
High Dose ◽  
Intensity Modulated ◽  
Radiation Delivery ◽  
Arc Therapy ◽  
Dose Volumes

Abstract Background: To evaluate the dosimetric parameters among three different radiotherapy techniques in patients with postoperative cervical cancer, including the Helical Tomotherapy (HT), the Volume Modulated Arc-Therapy (VMAT), and the Fixed-Field intensity modulated radiation therapy (FF-IMRT). Methods: Fifteen cervical cancer patients treated with postoperative radiotherapy were re-planning with HT, VMAT and FF-IMRT. The prescribed target dose of the patients was 1.8/45Gy. The paired-samples t-test was used to compare the dosimetric parameters of the planning target and OARs (Organs at risk), and the efficiency of radiation delivery. Results: Compared with the VMAT and FF-IMRT, the HT plans showed significant improvement in the conformity index (CI) and the homogeneity index (HI). In addition, the HT plans also significantly reduced the volume of high-dose region of the OARS, especially in the V30, V40 of small bowel, rectum and bladder. Meantime, the advantage of VMAT is that it reduced the treatment time and improved the efficiency of radiation delivery obviously, compared with the HT (293.8 ± 12.8s Vs. 557.6 ± 51.9s, P < 0.001) and FF-IMRT (293.8 ± 12.8s Vs. 581.8 ± 26.1s, P < 0.001). Conclusion: Our result reveals that HT showed better CI and HI for the target and reduced high dose volumes to OARs compared with VMAT and FF-IMRT, but the lower dose volumes to OARs increased slightly. As for the benefit of VMAT, it demonstrated the shortest treatment time. Our results could provide guidance for selecting the appropriate radiation technologies for cervical cancer patients who undergoing postoperative adjuvant pelvic radiotherapy.

Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis

2018 ◽  
Vol 49 (3) ◽  
pp. 263-269 ◽  
Author(s):  
Xiaoliang Liu ◽  
Weiping Wang ◽  
Qingyu Meng ◽  
Fuquang Zhang ◽  
Ke Hu
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Lymph Nodes ◽  
Field Intensity ◽  
Intensity Modulated Radiation Therapy ◽  
Concurrent Chemotherapy ◽  
Intensity Modulated ◽  
Genitourinary Toxicity ◽  
Extended Field ◽  
Grade 3

Abstract Objective This study was conducted to evaluate the efficacy and toxicity of extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy in patients with cervical cancer with positive para-aortic lymph nodes (PALN). Methods From September 2007 to December 2014, a total of 59 patients who had cervical cancer with para-aortic lymph node metastasis were treated with concurrent chemoradiotherapy at our institution. A dose of 45–50.4 Gy in 25–28 fractions with extended-field intensity-modulated radiation therapy was prescribed to planning target volume, and a dose of 30–36 Gy in 5–6 fractions was prescribed to Point A with high-dose-rate brachytherapy. A concurrent first-line cisplatin-based chemotherapy regimen was used. Results The median duration of follow-up was 32.1 months (range, 3.2–103.7 months). The 2- and 3-year overall survival, disease-free survival and local control rates were 69.0 and 52.8%, 45.0 and 41.3% and 83.4 and 81.0%, respectively. Distant metastasis was the major pattern of treatment failure, which occurred in 26 patients (44.1%). The incidence of Grade 3 or greater acute hematologic, gastrointestinal and genitourinary toxicity was 50.9, 1.7 and 3.4%, respectively. Only one patient had both Grade 3 late gastrointestinal and genitourinary toxicity. Conclusions The study found that extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy was safe and effective in patients who had cervical cancer with positive PALN.

Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience

2007 ◽  
Vol 25 (29) ◽  
pp. 4581-4586 ◽  
Author(s):  
Joseph K. Salama ◽  
Loren K. Mell ◽  
David A. Schomas ◽  
Robert C. Miller ◽  
Kiran Devisetty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Cancer Patients ◽  
Intensity Modulated Radiation Therapy ◽  
Complete Response ◽  
Concurrent Chemotherapy ◽  
Hiv Positive ◽  
Anal Canal Cancer ◽  
Intensity Modulated ◽  
Dermatologic Toxicity

PurposeTo report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT).Patients and MethodsFrom October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography–based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria.ResultsMedian follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively.ConclusionPreliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

Sign in / Sign up

Export Citation Format

Share Document